For Immediate Release
Chicago, IL – September 18, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Avanir Pharmaceuticals (AVNR-Free Report), NPS Pharmaceuticals (NPSP-Free Report), Orexigen (OREX-Free Report), Medivation (MDVN-Free Report) and Gilead (GILD-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday’s Analyst Blog:
Biotech Stock Roundup
Last week was eventful for the biotech sector with highlights including a couple of FDA approvals (Xtandi’s label expansion and Contrave) and a positive FDA panel outcome (Natpara). However, the biggest gainer was Avanir Pharmaceuticals (AVNR-Free Report), which came out with positive phase II data for the treatment of agitation in patients with Alzheimer's disease. Shares were up 85.3%.
Overall, the NASDAQ Biotechnology Index gained 0.55% last week (See the last biotech stock roundup here: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval)
Recap of the Week’s Most Important Stories
1. Avanir’s shares shot up on positive data from a phase II study conducted with AVP-923 for the treatment of agitation in patients with Alzheimer's disease. Considering the lack of FDA approved drugs for the treatment of agitation in Alzheimer's disease, there could be significant demand for AVP-923 once it is approved. The next step in the development process involves a meeting with the regulatory agencies to determine the advancement of the candidate into pivotal studies (read more: Avanir Pharmaceuticals Shoots Up on Positive AVP-923 Data).
2. NPS Pharmaceuticals’ (NPSP-Free Report) Natpara came up before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee last week. The FDA’s advisory panel voted 8 - 5 in favor of approving Natpara for the long-term treatment of hypoparathyroidism. A final response from the FDA should be out by Oct 24. However, with the panel raising some concerns, chances remain that the FDA action date could get delayed (read more: NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote).
3. Orexigen (OREX-Free Report) finally received FDA approval for its obesity drug, Contrave. Focus will now be on the commercialization of the drug. Partner Takeda’s marketing muscle should come in handy. Meanwhile, approval should also make it easier for Orexigen to find a partner for ex-North American territories (read more: Orexigen's Obesity Drug Contrave Approved by the FDA). Another company that gained FDA approval last week is Medivation (MDVN-Free Report). With this approval, Medivation’s prostate cancer treatment, Xtandi, can now be used in the pre-chemo patient population as well (read more: Medivation-Astellas' Xtandi's Label Expanded by FDA).
4. Gilead (GILD-Free Report) will be selling its high-priced hepatitis C virus (:HCV) treatment, Sovaldi, at a huge discount in developing countries. Not just Sovaldi but a combination treatment comprising Sovaldi and ledipasvir which is currently under review will also be provided in these countries which are estimated to account for about 54% of the total global infected population (read more: Gilead (GILD) Slips on Generic Sovaldi Licensing Deals).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on AVNR - FREE
Get the full Report on NPSP - FREE
Get the full Report on OREX - FREE
Get the full Report on MDVN - FREE
Get the full Report on GILD - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Read the analyst report on AVNR
Read the analyst report on NPSP
Read the analyst report on OREX
Read the analyst report on MDVN
Read the analyst report on GILD
Zacks Investment Research